109 related articles for article (PubMed ID: 24936714)
1. Cardiac risk factors: biomarkers and genetic tests to determine cardiovascular risk.
Anthony D; George P; Eaton CB
FP Essent; 2014 Jun; 421():11-5. PubMed ID: 24936714
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
3. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory markers in coronary heart disease.
Madjid M; Willerson JT
Br Med Bull; 2011; 100():23-38. PubMed ID: 22010105
[TBL] [Abstract][Full Text] [Related]
5. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
7. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
[TBL] [Abstract][Full Text] [Related]
8. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
10. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
11. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
12. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Persson M; Hedblad B; Nelson JJ; Berglund G
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
[TBL] [Abstract][Full Text] [Related]
13. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
Nestel PJ; Barnes EH; Tonkin AM; Simes J; Fournier M; White HD; Colquhoun DM; Blankenberg S; Sullivan DR
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2902-8. PubMed ID: 24092750
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Khakpour H; Frishman WH
Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
[TBL] [Abstract][Full Text] [Related]
15. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
18. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.
Li N; Li S; Yu C; Gu S
Postgrad Med; 2010 Jul; 122(4):200-5. PubMed ID: 20675983
[TBL] [Abstract][Full Text] [Related]
19. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
20. What is the role of alternative biomarkers for coronary heart disease?
Garg A
Clin Endocrinol (Oxf); 2011 Sep; 75(3):289-93. PubMed ID: 21521314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
